Onkologie. 2020:14(1):19-22 | DOI: 10.36290/xon.2020.008

Myocardial infarction as a clinical condition manifesting urinary bladder cancer

Hana Matějovská Kubešová
Klinika interní, geriatrie a praktického lékařství LF MU, Brno

The case report describes a 90 years old man of very good complex geriatric assessment results initially, suffering from urinary bladder carcinoma. There was inherited thrombophilia and carotic thrombosis 25 years ago with long term antithrombotic prophylaxis in the medical history. The urinary bladder carcinoma was asymptomatic until myocardial infarction with coronary intervention followed by dual antiplatelet therapy when macroscopic haematuria appeared. There is to consider the acceleration of coronary atherosclerosis as a result of concomitant inherited thrombophilia and malignancy. As a first examination to reveal the cause of hematuria, flexible urethroscopy was used and found only fragile endovesical mucosa. The vasoprotective treatment showed good effect. Haematuria relapsed after 4 months and invasive urothelial carcinoma was diagnosed using transabdominal sonography, CT urography and palliative transuretral tumor resection. Considering patient´s age and quckly deteriorating health status, palliative approach was applied.

Keywords: urinary bladder cancer, haematuria, myocardial infarction, antiaplatelet treatment, cystoskopy, sonography.

Received: February 3, 2020; Revised: February 3, 2020; Accepted: February 4, 2020; Prepublished online: February 4, 2020; Published: March 1, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Matějovská Kubešová H. Myocardial infarction as a clinical condition manifesting urinary bladder cancer. Onkologie. 2020;14(1):19-22. doi: 10.36290/xon.2020.008.
Download citation

References

  1. https://www.uroweb.cz/index.php?pg=dg-nadory-mocovehomechyre-epidemiologie-ceska-republika
  2. https://uroweb.org/guideline/non-muscle-invasive-bladdercancer/.
  3. Varga G, Pacík D. Nádory močového měchýře a urotelu In Matějovská Kubešová et al. Geriatrická onkologie. Praha: Mladá fronta, 2015: 431s.
  4. https://uroweb.org/guideline/bladder-cancer-muscle-invasiveand-metastatic/.
  5. Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013; 63(2): 234-241. Go to original source... Go to PubMed...
  6. Katolická J. Karcinom močového měchýře z pohledu klinického onkologa. Urol. praxi, 2014; 15(2): 72-76.
  7. O'Donnell, P.H., et al. Pembrolizumab (Pembro; MK-3475) for advanced urothelial cancer: Results of a phase IB study. J Clin Oncol, 2015; 33: 296. Go to original source...
  8. Balar AV, et al. Atezolizumab as first-line treatment in cisplatinineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet, 2017; 389: 67. Go to original source... Go to PubMed...
  9. Guglietta S, Rescigno M. Hypercoagulation and complement: Connected players in tumor development and metastases. Semin Immunol. 2016; 28(6): 578-586. Go to original source... Go to PubMed...
  10. Fujinami J, Ohara T, Kitani-Morii F, et al.Cancer-Associated Hypercoagulation Increases the Risk of Early Recurrent Stroke in Patients with Active Cancer. Cerebrovasc Dis. 2018; 46(1-2): 46-51. Go to original source... Go to PubMed...
  11. Selvik HA, Bjerkreim AT, Thomassen L, et al. When to Screen Ischaemic Stroke Patients for Cancer. Cerebrovasc Dis. 2018; 45(1-2): 42-47. Go to original source... Go to PubMed...
  12. Nam KW, Kim CK, Kim TJ, et al. Predictors of 30-day mortality and the risk of recurrent systemic thromboembolism in cancer patients suffering acute ischemic stroke. PLoS One. 2017; 12(3): e0172793. doi: 10.1371/journal.pone.0172793.eCollection 2017. Go to original source... Go to PubMed...
  13. Páramo Fernández JA. Atherosclerosis and clonal hematopoiesis: A new risk factor. Clin Investig Arterioscler. 2018; 30(3): 133-136. Go to original source...
  14. Groarke EM, Young NS. Aging and Hematopoiesis. Clin Geriatr Med. 2019; 35(3): 285-293. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.